GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XSWX:BIIB) » Definitions » E10

Biogen (XSWX:BIIB) E10 : CHF0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biogen E10?

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was CHF0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is CHF0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biogen's average E10 Growth Rate was 0.40% per year. During the past 3 years, the average E10 Growth Rate was 8.60% per year. During the past 5 years, the average E10 Growth Rate was 13.30% per year. During the past 10 years, the average E10 Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biogen was 186.40% per year. The lowest was -64.80% per year. And the median was 43.20% per year.

As of today (2024-05-18), Biogen's current stock price is CHF232.00. Biogen's E10 for the quarter that ended in Mar. 2024 was CHF0.00. Biogen's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Biogen was 110.75. The lowest was 9.39. And the median was 29.75.


Biogen E10 Historical Data

The historical data trend for Biogen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen E10 Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.92 15.30 - - -

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biogen's E10

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.



Biogen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

per share eps CPI Adj_EPS
201406 2.696 100.560 3.533
201409 3.392 100.428 4.451
201412 3.648 99.070 4.852
201503 3.420 99.621 4.524
201506 3.663 100.684 4.794
201509 4.036 100.392 5.298
201512 3.752 99.792 4.955
201603 4.346 100.470 5.700
201606 4.644 101.688 6.018
201609 4.584 101.861 5.930
201612 3.048 101.863 3.943
201703 3.465 102.862 4.439
201706 3.940 103.349 5.024
201709 5.573 104.136 7.052
201712 -1.392 104.011 -1.764
201803 5.252 105.290 6.573
201806 4.138 106.317 5.129
201809 6.923 106.507 8.566
201812 4.692 105.998 5.833
201903 7.154 107.251 8.790
201906 7.756 108.070 9.457
201909 8.311 108.329 10.110
201912 7.939 108.420 9.649
202003 7.751 108.902 9.379
202006 9.123 108.767 11.053
202009 4.080 109.815 4.896
202012 2.061 109.897 2.471
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Biogen  (XSWX:BIIB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Biogen was 110.75. The lowest was 9.39. And the median was 29.75.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biogen E10 Related Terms

Thank you for viewing the detailed overview of Biogen's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (XSWX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (XSWX:BIIB) Headlines

From GuruFocus

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024